Dosing and Coadministration

TRUMENBA offers a 2-dose option for adolescent and young adult patients.1
  • If the second dose is administered earlier than 6 months after the first dose, a third dose should be administered at least 4 months after the second dose1

Advisory Committee on Immunization Practices (ACIP) recommends the 2-dose schedule when given to healthy adolescents and young adults, aged 16 through 23 years who are not at increased risk for meningococcal disease, as a category B recommendation.2,3†

On average, young adults return to the doctor after 6 to 8 months.4‡

ACIP recommends the 3-dose schedule for persons aged ≥10 years, who are in a MenB outbreak situation or at increased risk for meningococcal disease, as a category A recommendation.§ These persons include those with persistent complement component deficiencies,|| those with anatomic or functional asplenia, or microbiologists routinely exposed to isolates of Neisseria meningitidis.

  • *The choice of dosing schedule may depend on the risk of exposure and the patient’s susceptibility to meningococcal serogroup B disease.1
  • Category B recommendations are made for individual clinical decision-making.
  • Data collected in March 2017 from a survey of 593 young adults (aged 16-21 years) and/or patients/caregivers across the United States.
  • §Category A recommendations are made for all persons in an age- or risk factor-based group.
  • ||Including inherited or chronic deficiencies in C3, C5-9, properdin, factor D, factor H, or who are taking eculizumab (Soliris®; Alexion Pharmaceuticals, Inc.).

Only TRUMENBA has been studied with other adolescent vaccines1,3

  • Concomitant administration did not significantly increase local reactions or systemic events compared with TRUMENBA alone5,6
The immunogenicity of concomitantly administered TRUMENBA with HPV4, MCV4, and Tdap vaccines was evaluated in adolescents.1
  • The noninferiority criteria were met for all immunogenicity endpoints for MenB strains, MCV4, and Tdap antigens, as well as for HPV antigens, with the exception of HPV-181
  • Seroconversion for all 4 HPV antigens was achieved by ≥99% of subjects in the groups that received HPV4 (secondary endpoint)5

Data are not available to assess the safety and immunogenicity of concomitant administration of TRUMENBA with other routine adolescent vaccines.1

  • HPV4=quadrivalent human papillomavirus vaccine; HPV=human papillomavirus; MCV4=quadrivalent meningococcal conjugate vaccine; MenB=serogroup B meningococcal disease; Tdap=tetanus, diphtheria, and pertussis vaccine.
Contact your Pfizer Sales Representative or call a Vaccine Specialist at
1-844-439-2571.